Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Novel CAR-T in Hematopoietic and Lymphoid Malignancies
NCT05513612Phase 1Withdrawn
- Sponsor
- Shanghai Pudong Hospital
- Start
- Aug 2020
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute myeloid leukemia (AML), B-cell non-Hodgkin lymphoma (B-NHL), multiple myeloma (MM) and 2 more, sponsored by Shanghai Pudong Hospital. Primary endpoints: Treatment-Emergent Adverse Events at 4 weeks, Treatment-Related Adverse Events at 4 weeks and 1 more. Planned start Aug 2020; status: withdrawn.
02
Conditions
acute myeloid leukemia (AML)B-cell non-Hodgkin lymphoma (B-NHL)multiple myeloma (MM)adult T-cell leukemia-lymphoma (ATLL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05513612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513612.